Testosterone Science

Research Summaries

Update on Testosterone Deficiency and Therapeutic Options for Testosterone Replacement Therapy

Population: Men

Citation

Update on testosterone deficiency and therapeutic options for testosterone replacement therapy

Thompson T, Mubarak M, Jones TH, Pearce I, Modgil V.

Nat Rev Urol. 2026. Published October 12, 2026.

PMID: 42864396 DOI: 10.1038/s41585-026-01190-3

Study at a Glance

Design
Narrative review

1. Question Addressed

How should clinicians diagnose testosterone deficiency, identify men likely to benefit from treatment, and select an appropriate testosterone formulation? This review examines symptomatic benefits, safety considerations, fertility, and monitoring across available and emerging therapeutic options (Thompson et al. 2026).

2. Plain Language Summary

Testosterone deficiency requires both relevant symptoms and repeatedly low blood testosterone levels. A low result alone does not establish the diagnosis. The review explains how to distinguish testicular or pituitary disease from potentially reversible suppression associated with obesity, illness, or medication use [8].

Testosterone treatment can improve sexual symptoms, correct some cases of anaemia, increase bone density, and change body composition in appropriately selected men. Improvements in fatigue, mood, and metabolic outcomes are less consistent. Increased bone density should not be interpreted as protection against fractures: a large trial found more clinical fractures with testosterone than placebo [7,8].

Gels, injections, oral preparations, pellets, and nasal or buccal products differ in convenience, absorption, and adverse effects. Treatment should reflect the patient's symptoms, preferences, comorbidities, and fertility plans. Testosterone can suppress sperm production, and specialist alternatives may be needed when conception is a priority. Monitoring remains essential even when blood testosterone returns to the normal range [8].

3. Study at a Glance

  • Design: Clinical narrative review, with 203 references; no new patient cohort or pooled statistical analysis.
  • Population: Adult men with suspected or confirmed testosterone deficiency. Underlying studies include men with ageing-related symptoms, obesity, diabetes, cardiovascular disease, and other causes of hypogonadism; there is no single sample size or age range for the review.
  • Sources Searched: Clinical guidelines, randomized trials, meta-analyses, observational studies, and pharmacokinetic studies are discussed. Databases, search strings, screening procedures, and eligibility criteria are not reported.
  • Period Covered: Literature includes publications from 2026, but no formal search start date, end date, or update procedure is specified.
  • Evidence Grading: Selected guideline evidence levels are described, but the review applies no uniform grading framework or formal risk-of-bias assessment of its own.
  • Scope: Diagnosis; sexual, haematological, skeletal, metabolic, psychological, cardiovascular, prostate, and fertility outcomes; formulation selection; and follow-up (Thompson et al. 2026).

4. Methods

The authors organize published evidence by diagnostic issue, clinical outcome, and treatment route. They compare recommendations from professional societies and discuss trial findings alongside observational and pharmacokinetic evidence. This is an expert synthesis rather than a systematic review, and the process used to select or weigh individual studies is not reproducible from the reported methods (Thompson et al. 2026).

The clinical framework distinguishes:

  • Primary Hypogonadism: Testicular failure, usually with elevated gonadotropins.
  • Secondary Hypogonadism: Hypothalamic or pituitary dysfunction, with low or inappropriately normal gonadotropins.
  • Functional Hypogonadism: Potentially reversible suppression associated with obesity, systemic disease, or medication exposure.

Therapeutic comparisons cover transdermal, oral, intramuscular, subcutaneous, subdermal, nasal, and buccal testosterone, together with specialist treatments that stimulate endogenous hormone production. The review has no common primary endpoint, prespecified statistical analysis, or review-level adjusted effect estimate (Thompson et al. 2026).

5. Key Findings

  • Diagnosis: Compatible symptoms should be accompanied by low testosterone on 2 separate morning measurements. Free testosterone and sex hormone-binding globulin can clarify borderline or discordant results. Gonadotropins help identify the cause, while reversible contributors and fertility intentions should be assessed before treatment. Diagnostic thresholds differ between guidelines (Thompson et al. 2026).
  • Sexual Function: The review reports a meta-analysis of 2,298 men in which testosterone improved erectile function by 2.31 points on the International Index of Erectile Function erectile-function domain compared with placebo (95% CI 1.41–3.22; p<0.0001). Benefit was concentrated in men with low baseline testosterone; these findings do not support treatment of men with normal testosterone solely for sexual symptoms (Thompson et al. 2026).
  • Anaemia and Erythrocytosis: Testosterone can improve deficiency-associated anaemia, but the same stimulation of red-cell production can cause erythrocytosis. Haemoglobin and haematocrit therefore require baseline and follow-up measurement. The review identifies haematocrit above 54% as requiring intervention rather than continued unchanged dosing (Thompson et al. 2026).
  • Bone Outcomes: Bone mineral density can improve without a reduction in fractures. In the TRAVERSE fracture substudy, 91/2,601 testosterone-treated men (3.50%) and 64/2,603 placebo-treated men (2.46%) sustained a clinical fracture over a median 3.19 years: hazard ratio 1.43 (95% CI 1.04–1.97). The proposed explanation of greater physical activity remains a hypothesis (Snyder et al. 2024; Thompson et al. 2026).
  • Body Composition and Metabolism: Lean mass generally increases and fat mass decreases, but findings for glycaemic control and diabetes prevention are inconsistent. The review contrasts favourable T4DM results with a negative TRAVERSE diabetes analysis. Differences in populations, formulations, achieved testosterone, and outcome definitions complicate comparisons; the review does not establish testosterone as a diabetes-prevention treatment (Thompson et al. 2026).
  • Mood, Vitality, and Cognition: Benefits are less uniform than those for sexual symptoms. The Testosterone Trials found small improvements in mood and depressive symptoms but no significant benefit on the primary vitality outcome. The review finds no established cognitive benefit (Snyder et al. 2016; Thompson et al. 2026).
  • Cardiovascular Safety: TRAVERSE randomized 5,246 men aged 45–80 years with hypogonadism and cardiovascular disease or elevated risk. Major cardiovascular events occurred in 7.0% with testosterone gel and 7.3% with placebo: hazard ratio 0.96 (95% CI 0.78–1.17; p<0.001 for noninferiority). This supports noninferiority within the trial's setting, not cardiovascular prevention. Atrial fibrillation, acute kidney injury, and pulmonary embolism were more frequent with testosterone (Lincoff et al. 2023).
  • Prostate and Urinary Outcomes: In the prospectively assessed TRAVERSE prostate study, high-grade cancer occurred in 5/2,596 men receiving testosterone and 3/2,602 receiving placebo: hazard ratio 1.62 (95% CI 0.39–6.77; p=0.51). Acute urinary retention and other assessed prostate events did not differ significantly. The wide confidence interval and exclusion of men at increased prostate-cancer risk limit reassurance for higher-risk populations (Bhasin et al. 2023).
  • Fertility: Exogenous testosterone suppresses gonadotropins and intratesticular testosterone and may cause oligospermia or azoospermia. It should be avoided in men actively seeking conception. Gonadotropin treatment and selected off-label therapies require specialist assessment; normalizing serum testosterone does not itself demonstrate restored fertility (Thompson et al. 2026).
  • Treatment Choice: Gels permit dose adjustment but require daily use and transfer precautions. Short-acting injections can produce concentration fluctuations and erythrocytosis; long-acting injections reduce dosing frequency but are less readily withdrawn. Oral testosterone undecanoate offers an alternative route with product-specific food, dosing, and blood-pressure considerations. Pellets require a procedure and are difficult to adjust after implantation. Nasal and buccal treatments require frequent dosing and can cause local irritation. No formulation is established as best for all patients (Thompson et al. 2026).
  • Follow-up: The review recommends reassessing clinical response at 3, 6, and 12 months, then annually, alongside appropriate laboratory and safety monitoring. Sampling time depends on the preparation. Continued treatment should depend on meaningful clinical benefit and acceptable safety, rather than normalization of a laboratory value alone (Thompson et al. 2026).

6. Limitations and Strengths Affecting Interpretation

Strengths

  • Clinical Breadth: Integrates diagnosis, comorbidities, efficacy, safety, fertility, and treatment logistics in a single review.
  • Practical Relevance: Explains how route, pharmacokinetics, treatment burden, and patient priorities affect formulation choice and follow-up.
  • Recognition of Evidence Limits: Distinguishes some observational associations from causal effects and acknowledges inconsistent metabolic findings and the absence of demonstrated fracture prevention (Thompson et al. 2026).

Limitations

  • Non-systematic Selection: No reproducible search strategy, formal eligibility criteria, or study-selection flow is provided, leaving susceptibility to selective citation.
  • Uneven Evidence Quality: Randomized, observational, pharmacokinetic, and patient-preference evidence are combined without a consistent quality-grading method.
  • Overinterpretation: Some broad safety statements and proposed explanations for adverse outcomes are more confident than the underlying evidence warrants. Noninferiority for major cardiovascular events does not establish the absence of all cardiovascular adverse effects (Lincoff et al. 2023; Thompson et al. 2026).
  • Limited Comparative Evidence: Biochemical normalization and satisfaction studies do not establish superior long-term clinical outcomes for a particular formulation (Thompson et al. 2026).
  • Reporting and Interests: The article contains inconsistencies in treatment details and descriptions of prior studies. It also discloses industry-related honoraria or travel support for 1 author, which is relevant when assessing an expert narrative synthesis (Thompson et al. 2026).

This review is useful for organizing clinical assessment and shared treatment decisions, but its broad therapeutic conclusions require checking against outcome-specific trials, guidelines, and product information (Thompson et al. 2026).

7. Authors' Conclusions

The authors conclude that testosterone therapy should principally relieve symptoms in men with confirmed deficiency. They consider improvements in sexual function, anaemia, bone density, body composition, mood, and quality of life possible in appropriately selected patients. They advocate individualized formulation selection, counselling, and monitoring, with attention to comorbidities, treatment access, and patient priorities (Thompson et al. 2026).

8. Commentary

The review consolidates established clinical principles rather than providing new comparative efficacy evidence. Its diagnostic approach is broadly consistent with the Endocrine Society guideline: symptoms must accompany consistently low testosterone, and the underlying cause should be investigated. Its emphasis on sexual benefit is supported by the Testosterone Trials, which enrolled 790 symptomatic men aged at least 65 years with testosterone below 275 ng/dL. Those trials also illustrate why mood, fatigue, and sexual function should be treated as distinct outcomes (Bhasin et al. 2018; Snyder et al. 2016; Thompson et al. 2026).

The main practical contribution is the integration of diagnostic evaluation with formulation selection. Reversible contributors, fertility plans, adherence, transfer risk, and the ability to adjust or stop treatment can change the preferred option. The review is less definitive about comparative long-term clinical outcomes because much of the formulation literature concerns testosterone concentrations or satisfaction rather than direct comparisons of symptoms and serious adverse events (Thompson et al. 2026).

Cardiovascular reassurance should remain specific to the evidence. TRAVERSE evaluated titrated transdermal gel with a mean treatment duration of 21.7 months and mean follow-up of 33.0 months. Its primary finding does not show that testosterone prevents cardiovascular disease or that every formulation has identical safety. The reported secondary adverse-event imbalances warrant attention; attributing them to COVID-19 on the basis of post hoc analyses does not by itself establish causation (Lincoff et al. 2023; Thompson et al. 2026).

Regulatory context has evolved. In February 2025, the FDA requested removal of boxed-warning language concerning increased adverse cardiovascular outcomes while requiring blood-pressure warnings. Its current information page also records June 2026 requests to remove the age-related hypogonadism limitation of use and revise prostate-cancer and benign-prostatic-hyperplasia safety information. These are regulatory labeling actions, not evidence that testosterone benefits men without confirmed deficiency; prescribing decisions still require attention to the applicable product label and clinical evaluation (FDA 2025; FDA 2026; Bhasin et al. 2018).

Skeletal and prostate outcomes require similarly restrained interpretation. Improved bone density has not translated into demonstrated fracture prevention, and the TRAVERSE fracture result argues against presenting testosterone as an established antifracture therapy. Low prostate-event rates in screened trial participants are reassuring, but few cancers and exclusion of higher-risk men limit extrapolation to men with known or suspected prostate cancer (Snyder et al. 2024; Bhasin et al. 2023).

The Review Supports Individualized Treatment for Men With Symptoms and Confirmed Testosterone Deficiency. Treatment Requires Regular Monitoring. Testosterone Therapy Can Improve Symptoms, but These Benefits Do Not Establish That It Prevents Diabetes, Fractures, or Cardiovascular Disease (Thompson Et Al. 2026).

9. References

1. Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744. DOI: https://doi.org/10.1210/jc.2018-00229. PubMed: https://pubmed.ncbi.nlm.nih.gov/29562364/

Supporting quote: “We recommend confirming the diagnosis by repeating the measurement of morning fasting total T concentrations.”

2. Bhasin S, Travison TG, Pencina KM, O'Leary M, Cunningham GR, Lincoff AM, et al. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial. JAMA Netw Open. 2023;6(12):e2348692. DOI: https://doi.org/10.1001/jamanetworkopen.2023.48692. PubMed: https://pubmed.ncbi.nlm.nih.gov/38150256/

Supporting quote: “incidences of acute urinary retention, invasive surgical procedure for BPH, or new pharmacologic treatment for LUTSs did not differ between the treatment groups.”

3. Food and Drug Administration (FDA). FDA issues class-wide labeling changes for testosterone products. 28 February 2025. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-issues-class-wide-labeling-changes-testosterone-products. DOI and PubMed: not applicable to this regulatory communication.

Supporting quote: “adding product-specific information on increased blood pressure for testosterone products with completed ABPM studies”.

4. Food and Drug Administration (FDA). Testosterone Information. Current agency webpage describing June 2026 labeling requests. Accessed 17 November 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/testosterone-information. DOI and PubMed: not applicable to this regulatory webpage.

Supporting quote: “FDA requested updates to testosterone prescribing information in June 2026.”

5. Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, et al.; TRAVERSE Study Investigators. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389(2):107–117. DOI: https://doi.org/10.1056/NEJMoa2215025. PubMed: https://pubmed.ncbi.nlm.nih.gov/37326322/

Supporting quote: “A higher incidence of atrial fibrillation, of acute kidney injury, and of pulmonary embolism was observed in the testosterone group.”

6. Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, et al.; Testosterone Trials Investigators. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016;374(7):611–624. DOI: https://doi.org/10.1056/NEJMoa1506119. PubMed: https://pubmed.ncbi.nlm.nih.gov/26886521/

Supporting quote: “men who received testosterone reported slightly better mood and lower severity of depressive symptoms than those who received placebo.”

7. Snyder PJ, Bauer DC, Ellenberg SS, Cauley JA, Buhr KA, Bhasin S, Miller MG, Khan NS, Li X, Nissen SE. Testosterone Treatment and Fractures in Men with Hypogonadism. N Engl J Med. 2024;390(3):203–211. DOI: https://doi.org/10.1056/NEJMoa2308836. PubMed: https://pubmed.ncbi.nlm.nih.gov/38231621/

Supporting quote: “testosterone treatment did not result in a lower incidence of clinical fracture than placebo.”

8. Thompson T, Mubarak M, Jones TH, Pearce I, Modgil V. Update on testosterone deficiency and therapeutic options for testosterone replacement therapy. Nat Rev Urol. Published online 12 October 2026. Volume and pages not yet assigned. DOI: https://doi.org/10.1038/s41585-026-01190-3. PubMed: https://pubmed.ncbi.nlm.nih.gov/42864396/

Supporting quote: “TTh is primarily aimed at relieving the symptoms of testosterone deficiency in men.”

All Research Summaries

Post a Comment or Question

Shared Decision Making

Bring the Evidence to Your Next Consultation

Use our patient resources and questionnaires to prepare questions about symptoms, testing and treatment options for your doctor.